Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.
A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.
The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
High-dose Lysine and Histidine supplements caused curly/kinky hair and shedding due to Elastin dysfunction. Minoxidil, white tea, and dark grape juice were mentioned as treatments to inhibit Elastase and mimic Lysyl Oxidase.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hair follicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.
Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.
The conversation is about creating a topical hair loss treatment with B6, zinc, and azelaic acid, which is claimed to inhibit 90% of scalp DHT. One user is skeptical about the effectiveness of this treatment and its comparison to other treatments without side effects.
The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.
Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.
A 26-year-old male with a family history of early baldness documents his hair loss journey, using finasteride, dutasteride, and Nizoral, along with lifestyle changes like weightlifting and a vertical diet. Despite some stabilization, he continues to experience thinning and remains determined to fight hair loss.
The conversation is about the effectiveness of Maneup GHK-Cu hair growth serum, a topical treatment for hair loss. The user is considering trying it but is skeptical due to issues others have had with DIY injections of a similar substance.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.
Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.